Silence Therapeutics PLC Silence Therapeutics Announces Leadership Change (1787Q)
04 June 2018 - 7:15PM
UK Regulatory
TIDMSLN
RNS Number : 1787Q
Silence Therapeutics PLC
04 June 2018
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
Silence Therapeutics Announces Leadership Change
4 June 2018
Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a
leader in the discovery, delivery and development of novel RNA
therapeutics for the treatment of serious diseases, announces today
that Ali Mortazavi is stepping down as Chief Executive Officer and
as a Director of the Company with immediate effect after having
served the Company for six years. Dr Annalisa Jenkins, Chair of
Silence Therapeutics, is today assuming the role of Executive Chair
in an interim capacity to ensure a smooth transition until a new
Chief Executive Officer is appointed.
Annalisa Jenkins, Executive Chair of the Board of Directors,
said: "On behalf of the Board I would like to thank Ali for his
achievements and commitment to Silence over the past six years.
Under his leadership Silence has built an experienced international
executive team with significant RNAi expertise that has established
a strong IP and technology platform in GalNAC-based siRNA. We
believe today that our RNAi platform and R&D capabilities offer
an opportunity to advance our lead programme in iron metabolism
towards the clinic and to establish research partnerships that will
maximise shareholder value. We wish Ali every success in his future
endeavours."
Dr Jenkins, MBBS, FRCP, joined Silence as Non-Executive Chair in
October 2017. She is the CEO of Plaquetec and serves on a number of
UK and International Life Science boards. She has 25 years of
international experience in building and leading teams that
advanced programmes from scientific research through clinical
development, regulatory approval and into healthcare systems
globally. Previous roles include positions as Head of Global
R&D for Merck Serono and Head of Global Medical Affairs for
Bristol-Myers Squibb. She also has recent experience in the fields
of gene therapy and rare diseases, having served as the CEO of
Dimension Therapeutics, Inc., until its acquisition in late
2017.
Enquiries:
Silence Therapeutics plc Tel: +44 (0) 20 3457
Annalisa Jenkins, Executive Chair 6900
David Ellam, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Broker) Tel: +44 (0) 20 7418
James Steel/ Oliver Jackson 8900
Media & IR Enquiries Tel: +44 (0) 20 3714
Optimum Strategic Communications 1789
Mary Clark/ Eva Haas/ Hollie Vile
silence@optimumcomms.com
IR Enquiries - US Tel: +1 (212) 213
Burns McClellan 0006
John Grimaldi
silence.therapeutics@burnsmc.com
Notes to Editors
About Silence Therapeutics plc
Silence Therapeutics is developing a new generation of medicines
by harnessing the body's natural mechanism of RNA interference, or
RNAi, within its cells. Our proprietary technology can selectively
inhibit any gene in the genome, specifically silencing the
production of disease-causing proteins. Using our enabling delivery
systems, we have achieved an additional level of specificity by
delivering our therapeutic RNA molecules exclusively to target
cells. Silence's proprietary RNA chemistries and delivery systems
are designed to improve the stability of our molecules and enhance
effective delivery to target cells, providing a powerful modular
technology well suited to tackle life-threatening diseases. For
more information, please visit:
http://www.silence-therapeutics.com/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAUGUAUQUPRUBC
(END) Dow Jones Newswires
June 04, 2018 05:15 ET (09:15 GMT)
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From Apr 2024 to May 2024
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024